Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET
Company Participants
Douglas S. Ingram – President, CEO & Director
Ian Estepan – Corporate Participant
Louise Rodino-Klapac – Corporate Participant
Conference Call Participants
Anupam Rama – JPMorgan Chase & Co, Research Division
Biren N. Amin – Piper Sandler & Co., Research Division
Brandon Richard Frith – Wolfe Research, LLC
Brian Corey Abrahams – RBC Capital Markets, Research Division
Caleb Kawun Stubbs – William Blair & Company L.L.C., Research Division
Charles Anderson Moore – Robert W. Baird & Co. Incorporated, Research Division
David Timothy Hoang – Deutsche Bank AG, Research Division
Eliana Rachel Merle – UBS Investment Bank, Research Division
Gil Joseph Blum – Needham & Company, LLC, Research Division
Huidong Wang – Barclays Bank PLC, Research Division
Lin Tsai – Jefferies LLC, Research Division
Michael Eric Ulz – Morgan Stanley, Research Division
Mitchell Swaroop Kapoor – H.C. Wainwright & Co, LLC, Research Division
Ritu Subhalaksmi Baral – TD Cowen, Research Division
Tommie M. Reerink – Goldman Sachs Group, Inc., Research Division
Uy Sieng Ear – Mizuho Securities USA LLC, Research Division
Will Devroe Soghikian – Leerink Partners LLC, Research Division
Yanan Zhu – Wells Fargo Securities, LLC, Research Division
Operator
Good morning, and welcome to Sarepta’s Conference Call to discuss the Update on Strategic Restructure and ELEVIDYS Label. As a reminder, today’s program is being recorded. At this time, I’ll turn the call over to Doug Ingram, CEO. Please go ahead.
Douglas S. Ingram
Thank you, Lisa. Let’s move to Slide 3, please. So first, before I begin, please note that we will be making forward-looking statements today. As always, please refer to our various public filings for the risks and uncertainties that come when making predictions about the future.
Next slide. Also, we
#Sarepta #Therapeutics #SRPT #Strategic #Restructure #ELEVIDYS #Label #Update #Call #Transcript